Hypertension, use of antihypertensive medications and breast cancer survival among Black women Authors: Mollie E Barnard, Nuo N Xu, Etienne X Holder, Dennis Jones, Matthew Nayor, Naomi Y Ko, Julie R Palmer Published: 2026 ABSTRACT AbstractBlack women in the United States experience disproportionately high breast cancer mortality and have high rates of comorbid hypertension; however, the associations of hypertension and antihypertensive medication use with breast cancer survival are unclear. We examined these associations among 2474 Black Women’s Health Study participants with invasive breast cancer. Hypertension and antihypertensive medication use were assessed biennially, and breast cancer diagnoses were confirmed through medical records and cancer registries. We used Cox proportional hazards models, adjusted for clinical and lifestyle factors and cancer treatment, to estimate hazard ratios (HR) for breast cancer-specific death. In the full study population, the HR for untreated hypertension compared to no hypertension was 1.17 (95% CI = 0.75–1.82), while the HR for treated hypertension compared to no hypertension was 0.81 (95% CI = 0.60–1.10). For ER+ cases, there was no association between untreated hypertension and breast cancer specific-death (HR = 0.96, 95% CI = 0.50–1.82), but a strong inverse association between treated hypertension and breast cancer-specific death (HR = 0.53, 95% CI = 0.34–0.83). In contrast, for ER- cases, we observed an increased risk of breast cancer specific death among those with untreated hypertension (HR = 2.19, 95% CI = 1.09–4.39), but there was little evidence of an association with treated hypertension (HR = 1.32, 95% CI = 0.80–2.19). Overall, our findings indicate that Black breast cancer patients with hypertension have better survival when their hypertension is treated, possibly due to regular healthcare engagement or the tumor suppressing actions of antihypertensive medications. Randomized trials are needed to establish causality and inform optimal cardiovascular management in oncology.Supplementary InformationThe online version contains supplementary material available at 10.1186/s13058-026-02317-5.Keywords: Breast neoplasms, Hypertension, Antihypertensive agents, Survival analysis, Health disparities Introduction In the United States (US) Black women with breast cancer are 38% more likely to die from their cancer when compared to White women with breast cancer [1]. Comorbid hypertension, which is at least 50% more common among Black versus White women, has been described as an important contributor to this disparity [2–4], yet the associations between hypertension, antihypertensive drug use and breast cancer survival are not fully understood. Results from prior epidemiologic studies of hypertension and breast cancer survival have not been consistent. The Kaiser Permanente Northern California Comorbidity Study observed an increased risk of recurrence (HR = 1.60, 95% CI 1.07–2.40) and a non-statistically significant increased risk of breast cancer-specific mortality (HR = 1.49, 95% CI 0.95–2.34) among Black women with hypertension when compared to Black women without hypertension [3]; however, results from White women in the same study were not statistically significant for either recurrence (HR = 1.22, 0.86–1.73) or mortality (HR = 1.24, 0.85–1.80) [3], and results from Asian women enrolled in the Shanghai Breast Cancer Survival Study suggested a possible inverse association between hypertension and both breast cancer recurrence (HR = 0.83, 0.67–1.03) and breast cancer-specific mortality (HR = 0.82, 0.64–1.04) [5]. These conflicting results may reflect genuine differences in the associations between hypertension and breast cancer outcomes across US racial groups, emphasizing the need for more research on this topic in Black women and in other populations with high rates of hypertension; however, it is also plausible that these discrepancies are driven by variations in how antihypertensive medications have been prescribed and used across different populations and time periods [6–8]. There are several classes of antihypertensive medications, most of which have not been well-studied with respect to breast cancer mortality. Beta blockers have become less popular over time, particularly as first-line treatment for hypertension, yet they have been studied most extensively [7]. Most studies of beta blockers indicate either no association or a weak inverse association with breast cancer-specific death [9–17]; however, multiple subtype-specific analyses have indicated that beta blocker use may be associated with a lower risk of breast cancer-specific death for triple-negative breast cancer (TNBC) patients [15, 18, 19]. Data from pre-clinical studies suggest that angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs), which are increasingly used as first-line antihypertensives [7], may also have anti-tumor properties [20, 21]; however, not all epidemiologic and clinical studies have supported this hypothesis [16, 22, 23]. To our knowledge, only one study has reported a strong positive association between ARB use and breast cancer survival [17], and no studies have observed a similar association for ACE inhibitors. Studies of calcium channel blockers, which have also increased in popularity as a first line treatment [7], have generally demonstrated no association with breast cancer outcomes [16, 17, 24], and studies of diuretics have indicated either no association [16] or poorer breast cancer-specific survival [17]. The goal of the present study was to better understand the associations of hypertension and antihypertensive drug use with breast cancer survival in US Black women. We evaluated antihypertensive medication use overall (as a proxy for blood pressure control) and by medication class (to reflect the different indications and mechanisms of action for each medication type). Methods Study population The Black Women’s Health Study (BWHS) is a US-based prospective cohort study that began in 1995 when 59,000 Black women located across the US returned baseline questionnaires that asked about their health and lifestyle [25]. Since 1995, BWHS participants have continued to actively participate in the study by completing biennial questionnaires that ask about their current lifestyle, medication use, and any changes to their health, including new cancer diagnoses. The present study included BWHS participants with invasive breast cancer. Ascertainment and characterization of breast cancer cases Incident invasive breast cancer cases (n = 3056) were initially identified via self-report, death records, or linkage to one of 31 cancer registries that cover the residential addresses of 95% of participants. Cases were confirmed by medical record review or, when medical records were not available, through review of cancer registry records. Medical records and cancer registry data were also used to determine stage at diagnosis and ER status. Breast cancer treatment information was obtained by cross-referencing medical records and cancer registry data with self-reported information on post-diagnosis surgery, radiation, chemotherapy, and hormone treatments (i.e., Tamoxifen, anastrozole, letrozole, goserelin, leuprolide, exemestane, fulvestrant). Cases with missing data on diagnosis year (n = 80), cases who were stage 4 at diagnosis (n = 69), cases with no active follow-up after their breast cancer diagnosis (n = 423), and cases who died within 12 months of diagnosis (n = 10) were excluded from this analysis, leaving a final analytic sample size of 2474. These 2474 participants were followed from their date of breast cancer diagnosis, until the first of the following events: death from breast cancer, death from cardiovascular disease (CVD), death from another cause, loss to follow-up, or 12/31/2022. Participant deaths and cause of death were recorded following notice from next-of-kin or the US postal service and following yearly searches of the National Death Index. Deaths were classified according to ICD codes, with breast cancer deaths defined as those with breast cancer recorded as the underlying cause of death. Ascertainment of hypertension, antihypertensive medication use, and covariates Hypertension and antihypertensive medication use were queried at the start of the BWHS in 1995 and every two years thereafter. Consistent with our prior work, women were classified as having hypertension once they had reported both a physician diagnosis of hypertension and antihypertensive medication use [26]. This measure of “clinical diagnosis of hypertension” has been validated within the BWHS with a positive predictive value of 99% when compared to participants’ medical records [27]. In the present study, once a participant was classified as having hypertension she was assumed to have hypertension for the rest of the study period. Participants contributed person-time to the “never hypertension” exposure category until classified as having hypertension. Once they were classified as having hypertension, they contributed person-time to the “hypertension, no current treatment” exposure category when they had not reported antihypertensive medication on their most recently completed questionnaire. Likewise, they contributed person-time to the “hypertension, current treatment” exposure category when they had reported use of any antihypertensive medication on their most recently completed questionnaire. Results for person-time characterized by antihypertensive medication use in the absence of a current or past diagnosis of hypertension were considered non-interpretable and were not reported. In sub-analyses of hypertension treated with specific medications, antihypertensive medications were classified by our study research pharmacist as ACE inhibitors, ARBs, beta blockers, calcium channel blockers, or diuretics. Topical urea products, over-the-counter diuretics like pamabrom, and dietary supplements containing natural diuretics were not included as antihypertensive medications. Women taking multiple antihypertensive medications contributed person-time to all relevant exposure categories. ACE inhibitors and ARBs were analyzed together since they both act on the renin-angiotensin-aldosterone system. Potential confounders were selected a priori based on plausible causal pathways. Covariates included cancer characteristics and treatments (assessment described above) and age at cancer diagnosis (continuous), as well as variables queried on biennial questionnaires: education (≤ 12 years, 13–15 years, ≥ 16 years), exposure to neighborhood concentrated disadvantage (as determined from the participant’s time-updated residential address, in quartiles) [28], body mass index (BMI; <25, 25–29, 30–34, ≥ 35), smoking status (current/past/never), alcoholic drinks per week (< 1, 1–6, ≥ 7), vigorous physical activity (< 5 h per week, ≥ 5 h per week), personal history of diabetes (ever/never), and personal history of hyperlipidemia (ever/never). Apart from cancer characteristics, treatments, and age at cancer diagnosis, all covariate data were time-updated on return of subsequent biennial questionnaires. Statistical analyses We used Cox proportional hazards (PH) models to estimate hazard ratios (HR) and 95% confidence intervals (CIs) describing the associations of time-updated untreated and treated hypertension with all-cause mortality, and Cox PH models with censoring at the time of death due to other causes to estimate HRs and 95% CIs for associations of time-updated untreated and treated hypertension with breast cancer-specific mortality. Time since diagnosis was used as the time scale, and there was no evidence of crossing hazards over the study period. Fine-Gray models that more explicitly accounted for competing deaths due to CVD were also considered. Multivariable-adjusted models were adjusted for age, stage, education, neighborhood concentrated disadvantage, BMI, smoking, alcohol consumption, vigorous physical activity, type II diabetes, hyperlipidemia, and cancer treatments. Models evaluating the use of specific antihypertensive medications were mutually adjusted for use of all other antihypertensive medications. In addition to analyses in the full study population, we also conducted analyses stratified by stage at diagnosis and ER status. All analyses were conducted using SAS 9.4 (SAS Institute, Cary, NC). Statistical tests were two-sided with α = 0.05. Results Of the 2474 invasive breast cancer cases included in this analysis, 1253 were diagnosed at stage I, 868 at stage II, 246 at stage III, and 107 were missing stage at diagnosis. Frequencies of cancer characteristics, cancer treatments, and participant characteristics by hypertensive status and use of anti-hypertensive medications are presented in Table 1. Table 1Characteristics of 2474 BWHS participants at the time of invasive breast cancer diagnosisaNo hypertension (n = 1081)Treated hypertension (n = 1183)Untreated hypertension (n = 155)Age, n (%) < 4099 (9.2)13 (1.1)2 (1.3) 40–49378 (35.0)133 (11.3)17 (11.0) 50–59354 (32.8)366 (30.9)47 (30.3) 60–69193 (17.8)431 (36.4)57 (36.8) ≥ 7057 (5.2)240 (20.3)32 (20.6)Stageb, n (%) I499 (48.5)646 (56.9)84 (55.6) II421 (41.0)378 (33.3)48 (31.8) III108 (10.5)111 (9.8)19 (12.6)Estrogen receptor statusb, n (%) Positive608 (66.1)789 (72.5)90 (66.2) Negative312 (33.9)300 (27.5)46 (33.8)Chemotherapyb, n (%) Yes557 (57.6)499 (46.8)75 (53.2) No410 (42.4)567 (53.2)66 (46.8)Hormone therapyb, n (%) Yes365 (42.6)490 (52.0)52 (41.3) No491 (57.4)452 (48.0)74 (58.7)Surgery and radiation combinedb, n (%) Mastectomy378 (41.2)372 (37.6)48 (38.7) Lumpectomy with radiation408 (44.5)460 (46.5)61 (49.2) Lumpectomy without radiation66 (7.2)75 (7.4)8 (6.5) Lumpectomy with unknown radiation65 (7.1)83 (8.5)7 (5.6)Education, n (%) ≤ 12134 (12.4)199 (16.8)28 (18.1) 13–15255 (23.6)354 (29.9)60 (38.7) ≥ 16692 (64.0)630 (53.3)67 (43.2)Neighborhood concentrated disadvantageb, n (%) Quartile 1298 (29.7)281 (25.3)39 (27.1) Quartile 2273 (27.2)256 (23.1)30 (20.8) Quartile 3242 (24.1)286 (25.7)36 (25.0) Quartile 4191 (19.0)288 (25.9)39 (27.1)Body mass indexb, n (%) < 25314 (29.3)161 (13.8)32 (20.8) 25–29387 (36.1)384 (32.9)47 (30.5) 30–34227 (21.2)321 (27.6)40 (26.0) 35+143 (13.4)300 (25.7)35 (22.7)Smoking, n (%) Current97 (9.0)102 (8.6)13 (8.3) Past276 (25.5)424 (35.8)48 (31.0) Never708 (65.5)657 (55.6)94 (60.7)Alcohol consumptionb, n (%) < 1 drink/week656 (67.4)737 (70.9)95 (71.4) 1–6 drinks/week273 (28.0)251 (24.2)31 (23.3) 7 + drinks/week45 (4.6)51 (4.9)7 (5.3)Vigorous physical activityb, n (%) None443 (46.5)614 (60.5)64 (52.9) < 5 h/week437 (46.0)339 (33.4)45 (37.2) ≥ 5 h/week71 (7.5)62 (6.1)12 (9.9)Ever Type II diabetes, n (%)79 (7.3)355 (30.0)40 (25.8)Ever hyperlipidemia, n (%)343 (31.7)746 (63.1)87 (56.1)aThis table does not include data from the 55 participants who had no self-reported history of hypertension but were taking anti-hypertensive medicationsbThere were 107 missing values for stage, 276 for estrogen receptor status, 249 for chemotherapy, 502 for hormone therapy, 396 for surgery and/or radiation therapy, 167 for neighborhood concentrated disadvantage, 28 for body mass index, 55 for smoking, 279 for alcohol consumption, and 344 for vigorous physical activity Characteristics of 2474 BWHS participants at the time of invasive breast cancer diagnosisa aThis table does not include data from the 55 participants who had no self-reported history of hypertension but were taking anti-hypertensive medications bThere were 107 missing values for stage, 276 for estrogen receptor status, 249 for chemotherapy, 502 for hormone therapy, 396 for surgery and/or radiation therapy, 167 for neighborhood concentrated disadvantage, 28 for body mass index, 55 for smoking, 279 for alcohol consumption, and 344 for vigorous physical activity This cohort had a median follow-up time of 7.3 years (interquartile range: 3.3–13.0 years), during which time we observed 250 breast cancer-specific deaths, 49 deaths from CVD, and 128 deaths from other causes. The associations of untreated and treated hypertension with breast cancer-specific mortality are reported in Table 2, and the associations of untreated and treated hypertension with all-cause mortality can be found in Supplemental Table 1. The HR for breast cancer-specific mortality for individuals with untreated hypertension was 1.17 (95% CI = 0.75–1.82) when compared with women who never had hypertension. In contrast, those with treated hypertension had HR = 0.81 (95% CI = 0.60–1.10). For results by medication class, HRs were 0.72 (95% CI = 0.46–1.15) for ARBs or ACE inhibitors, 0.80 (95% CI = 0.47–1.39) for beta blockers, 0.73 (95% CI = 0.44–1.23) for calcium channel blockers, and 1.00 (95% CI = 0.65–1.55) for diuretics. Given the relative rarity of CVD deaths, the similar results for all-cause mortality (Supplemental Table 1), and the near identical results generated when using our non-informative censoring approach versus a Fine-Gray model with breast cancer death and death from CVD modeled as competing risks (Table 2 vs. Supplemental Table 2), all subsequent analyses used Cox PH models with breast cancer-specific death as the outcome of interest and censoring at death from CVD. Table 2Breast cancer mortality among 2474 BWHS invasive breast cancer cases by hypertensive status and current antihypertensive drug useDeaths (n)Person-monthsModel IModel IIModel IIIHR (95% CI)*HR (95% CI)†HR (95% CI)‡Never hypertension120100,425(Ref)(Ref)(Ref)Hypertension130157,4470.80 (0.61, 1.04)–0.87 (0.65, 1.16)§Hypertension, no current treatment2822,2671.19 (0.78, 1.83)–1.17 (0.75, 1.82)§Hypertension, any current treatment102135,1800.73 (0.55, 0.97)–0.81 (0.60, 1.10)§ARB or ACE inhibitor4972,1640.67 (0.47, 0.94)0.67 (0.43, 1.03)0.72 (0.46, 1.15)Beta blocker3039,4730.73 (0.48, 1.11)0.75 (0.44, 1.28)0.80 (0.47, 1.39)Calcium channel blocker3144,5360.67 (0.44, 1.01)0.70 (0.42, 1.16)0.73 (0.44, 1.23)Diuretic5066,3670.76 (0.54, 1.07)0.89 (0.58, 1.37)1.00 (0.65, 1.55)Unspecified medication68,4390.70 (0.31, 1.60)0.70 (0.31, 1.60)0.72 (0.31, 1.65)HR, hazard ratio; ARB, angiotensin receptor blocker; ACE, angiotensin-converting enzyme*Model I adjusts for age, stage, and ER status†Model II adjusts for age, stage, ER status, and other antihypertensive medications‡Model III adjusts for age, stage, ER status, education, neighborhood concentrated disadvantage, BMI, smoking, alcohol consumption, vigorous physical activity, type II diabetes, hyperlipidemia, cancer treatments and other antihypertensive medications§Model III without adjustment for other antihypertensive medications Breast cancer mortality among 2474 BWHS invasive breast cancer cases by hypertensive status and current antihypertensive drug use HR, hazard ratio; ARB, angiotensin receptor blocker; ACE, angiotensin-converting enzyme *Model I adjusts for age, stage, and ER status †Model II adjusts for age, stage, ER status, and other antihypertensive medications ‡Model III adjusts for age, stage, ER status, education, neighborhood concentrated disadvantage, BMI, smoking, alcohol consumption, vigorous physical activity, type II diabetes, hyperlipidemia, cancer treatments and other antihypertensive medications §Model III without adjustment for other antihypertensive medications We did not observe differences in the associations of hypertension, antihypertensive use and breast cancer mortality by stage at diagnosis (Table 3). Analyses stratified by ER-status suggested no association between untreated hypertension and breast cancer mortality for ER+ cases (HR = 0.96, 95% CI = 0.50–1.82, Table 4), but a positive association between untreated hypertension and breast cancer mortality for ER- breast cancer cases (HR = 2.19, 95% CI = 1.09–4.39, Table 4). We observed inverse associations between treated hypertension and breast cancer mortality among women with ER+ breast cancer, both overall (ER + HR = 0.53, 95% CI 0.34–0.83) and by medication class (ER + HRs of 0.44 [0.21–0.91] for ARBs/ACE inhibitors, 0.61 [0.26–1.42] for beta blockers, 0.48 [0.22–1.04] for calcium channel blockers and 0.41 [0.20–0.85] for diuretics). Inverse associations between treated hypertension and breast cancer mortality were not observed for ER- breast cancer (ER- HR = 1.32, 95% CI = 0.80–2.19). Table 3Breast cancer mortality among 2367 BWHS invasive breast cancer cases by hypertensive status and current antihypertensive drug use, stratified by stage*Deaths (n)Person-monthsMultivariable-adjusted HR (95% CI)**Deaths (n)Person-monthsMultivariable-adjusted HR (95% CI)**Stage I at diagnosis (n = 1253)Stage II or III at diagnosis (n = 1114)Never hypertension2248,520(Ref)8848,852(Ref)Hypertension2986,7590.94 (0.48, 1.81)§9367,4610.85 (0.61, 1.19)§Hypertension, no current treatment512,2501.09 (0.38, 3.08)§229,5631.30 (0.78, 2.15)§Hypertension, any current treatment2474,5090.91 (0.46, 1.80)§7157,8980.77 (0.54, 1.10)§ARB or ACE inhibitor1239,4430.76 (0.28, 2.04)3531,4080.77 (0.45, 1.33)Beta blocker921,3781.32 (0.43, 4.07)2017,3950.74 (0.38, 1.42)Calcium channel blocker924,5501.08 (0.38, 3.05)1918,9890.64 (0.34, 1.21)Diuretic1337,4571.15 (0.45, 2.98)3427,5541.00 (0.60, 1.68)Unspecified medication04,772–53,4380.86 (0.34, 2.15)HR, hazard ratio; ARB, angiotensin receptor blocker; ACE, angiotensin-converting enzyme*Analysis excludes 107 cases with unknown stage**Model adjusts for age, stage (stage II/III only), ER status, education, neighborhood concentrated disadvantage, BMI, smoking, alcohol consumption, vigorous physical activity, type II diabetes, hyperlipidemia, cancer treatments and other antihypertensive medications§Main model without adjustment for other antihypertensive medications Breast cancer mortality among 2367 BWHS invasive breast cancer cases by hypertensive status and current antihypertensive drug use, stratified by stage* HR, hazard ratio; ARB, angiotensin receptor blocker; ACE, angiotensin-converting enzyme *Analysis excludes 107 cases with unknown stage **Model adjusts for age, stage (stage II/III only), ER status, education, neighborhood concentrated disadvantage, BMI, smoking, alcohol consumption, vigorous physical activity, type II diabetes, hyperlipidemia, cancer treatments and other antihypertensive medications §Main model without adjustment for other antihypertensive medications Table 4Breast cancer mortality among BWHS invasive breast cancer cases by hypertensive status and current antihypertensive drug use, stratified by ER status*Deaths (n)Person-monthsMultivariable-adjusted HR (95% CI)**Deaths (n)Person-monthsMultivariable-adjusted HR (95% CI)**ER+ breast cancer cases (n = 1519)ER- breast cancer cases (n = 679)Never hypertension5157,656(Ref)4128,051(Ref)Hypertension5899,2190.59 (0.38, 0.90)§5541,2581.45 (0.89, 2.35)§Hypertension, no current treatment1413,3410.96 (0.50, 1.82)§136,0622.19 (1.09, 4.39)§Hypertension, any current treatment4485,8780.53 (0.34, 0.83)§4235,1961.32 (0.80, 2.19)§ARB or ACE inhibitor2445,9870.44 (0.21, 0.91)2119,4081.10 (0.55, 2.23)Beta blocker1524,1900.61 (0.26, 1.42)1410,8351.46 (0.61, 3.50)Calcium channel blocker1630,0170.48 (0.22, 1.04)1010,3450.83 (0.34, 2.05)Diuretic2243,6130.41 (0.20, 0.85)2215,8192.46 (1.23, 4.91)Unspecified medication35,3780.46 (0.14, 1.52)12,0420.55 (0.07, 4.10)ER, estrogen receptor; HR, hazard ratio; ARB, angiotensin receptor blocker; ACE, angiotensin-converting enzyme*Analysis excludes 276 cases with unknown ER status**Model adjusts for age, stage, education, neighborhood concentrated disadvantage, BMI, smoking, alcohol consumption, vigorous physical activity, type II diabetes, hyperlipidemia, cancer treatments and other antihypertensive medications. For ER+, treatments include chemotherapy, radiation, and hormone therapy. For ER-, treatments include chemotherapy and radiation§Main model without adjustment for other antihypertensive medications Breast cancer mortality among BWHS invasive breast cancer cases by hypertensive status and current antihypertensive drug use, stratified by ER status* ER, estrogen receptor; HR, hazard ratio; ARB, angiotensin receptor blocker; ACE, angiotensin-converting enzyme *Analysis excludes 276 cases with unknown ER status **Model adjusts for age, stage, education, neighborhood concentrated disadvantage, BMI, smoking, alcohol consumption, vigorous physical activity, type II diabetes, hyperlipidemia, cancer treatments and other antihypertensive medications. For ER+, treatments include chemotherapy, radiation, and hormone therapy. For ER-, treatments include chemotherapy and radiation §Main model without adjustment for other antihypertensive medications Discussion In this prospective analysis of 2474 US Black women with invasive breast cancer, women with treated hypertension had a lower risk of breast cancer mortality when compared with women with untreated hypertension and women who had never been diagnosed with hypertension. All antihypertensive drug classes (i.e., ARBs/ACE inhibitors, beta blockers, calcium channel blockers) were associated with a lower risk of ER+ breast cancer death, though associations varied in magnitude. This suggests that a combination of factors, including the mechanisms of action specific to different antihypertensive medications and the routine interactions with the medical system that are needed to maintain consistent treatment of hypertension, may be driving the lower risk of breast cancer death in women with treated hypertension. While prior epidemiological studies have not reported consistent associations between any specific antihypertensive drug class and breast cancer survival [9–24], the results of pre-clinical studies have emphasized the potential for class-specific effects of antihypertensive medications on breast cancer progression. In murine models, ARBs and ACE inhibitors have been reported to indirectly attenuate tumor growth through changes in tumor microvasculature and polarization of neutrophils toward an antitumoral phenotype [29, 30]. ARBs also have been hypothesized to directly attenuate tumor progression through their role as angiotensin II receptor type I (AGTR1) antagonists. Multiple pre-clinical studies across several cancer types, including breast, ovarian, glioma, and pancreatic cancers have demonstrated that preclinical therapeutic inhibition of AGTR1 using AGTR1 antagonists suppresses cancer cell proliferation and invasion and reduces VEGF production, thereby inhibiting angiogenesis [20, 31–33]. Notably, AGTR1 is highly overexpressed in 10–20% of breast cancers—typically ER+/ERBB2− tumors [34]. Therefore, consistent with the results of the present study, we would expect to see better breast cancer survival for users of both ARBs and ACE inhibitors, and especially for users of ARBs who have been diagnosed with ER+ breast cancer. Beta blockers have been posited to influence cancer survival by inhibiting cellular processes involved in cancer cell migration and angiogenesis. Data from both in vitro and in vivo studies have indicated that inhibition of beta-adrenergic receptor signaling limits cancer cell migration [35–38]. Another in vitro study indicated potential inhibition of pro-angiogenic factors (e.g., VEGF) with use of a beta-adrenergic receptor antagonist [39]. Some, but not all, calcium channel blockers have been reported to slow breast tumor proliferation and migration in vivo [40, 41] and in vitro [42, 43]; however, the mechanisms underlying these associations are not well established. One recent study described the slowing of tryptophan metabolism and its subsequent impact on tumor immune response as a possible mechanism, but this mechanism is likely not shared across all calcium channel blockers [44]. We are not aware of any preclinical studies of diuretics and their impact on breast cancer growth or outcomes. Blood pressure control, independent of each antihypertensive’s mechanism of action, may also be important to breast cancer outcomes. Healthy blood pressure has been hypothesized to reduce tumor-promoting pathways activated by chronic vascular injury, to improve chemotherapy delivery through improved tolerability and perfusion, and to decrease systemic inflammation [45, 46]. Regular clinic visits, as would be needed to have continued access to antihypertensive medications and to maintain blood pressure control, may also play a role in reducing risk of breast cancer death among those treated for hypertension. Women who regularly see a primary care physician are more likely to share any health concerns they may have with a medical professional and are also more likely to regularly access mammography, leading to earlier detection of a second primary breast cancer or breast cancer recurrence [47]. Strengths of our study include the large, prospective design and availability of detailed data on comorbidities, medication exposures, and cancer outcomes, as well as our focus on US Black women who, despite their high rates of hypertension and use of antihypertensive medications have been underrepresented in breast cancer pharmacoepidemiology research. This study also had several important limitations. First, it is possible that the “never hypertension” group included individuals who were unaware of their high blood pressure, though the results of a prior BWHS validation study suggest that the proportion of individuals with undiagnosed high blood pressure is small and unlikely to affect our findings [27]. Second, we combined those who no longer needed antihypertensives, those who had lost access to antihypertensives, and those who were non-adherent in their use of antihypertensives into a single category of “hypertension, no current treatment”. Third, we were limited in our ability to detect modest drug class-specific differences, particularly for less frequently used agents, and we did not have adequate exposed case counts to look at simultaneous use of specific combinations of antihypertensives. Fourth, we were unable to adjust for cardiometabolic diseases that may influence both hypertension risk and/or anti-hypertensive use and survival; however, this was largely due to the very low prevalence of most of these conditions (e.g., chronic kidney disease, history of MI, history of stroke). Confounding by indication for medications with multiple indications for use, e.g., beta-blockers and diuretics, also remains a concern. In conclusion, our findings underscore the importance of identifying and treating hypertension in breast cancer patients. Future research should explore the biological pathways connecting hypertension, antihypertensive medication use, and cancer progression; evaluate the role of treatment type, timing, and duration; and further investigate potential differences in associations by tumor subtype. Ultimately, randomized trials may be needed clarify causality and inform evidence-based cardiovascular management in oncology care—both during treatment and after active treatment. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1. Acknowledgements We would like to thank the participants and staff of the Black Women’s Health Study for their important contributions. Author contributions Contributions to the conceptualization, design, and supervision: M.E.B., J.R.P. Funding acquisition and data collection: J.R.P. Data analysis: N.N.X. Original draft preparation: M.E.B. All authors (M.E.B., N.N.X., E.X.H., D.J., M.N., N.Y.K., and J.R.P.) participated in the interpretation of the findings and participated in manuscript review and editing. All authors have approved the submitted version of the manuscript. Funding This work was supported by the National Institutes of Health [grant number U01 CA164974] and Susan G. Komen [grant number SAC220228]. The authors also acknowledge contributions to this study from central cancer registries supported through the Centers for Disease Control and Prevention’s National Program of Cancer Registries and/or the National Cancer Institute’s Surveillance, Epidemiology, and End Results Program. Central registries may also be supported by state agencies, universities, and cancer centers. Participating central cancer registries include the following: AL, AR, AZ, CA, CO, CT, DE, DC, FL, GA, HI, IA, IL, IN, KY, LA, MD, MA, MI, MO, MS, NE, NJ, NM, NY, NC, OH, OK, OR, PA, SC, TN, TX, VA, WA, and WI. Dr. Barnard received support from the Dahod Breast Cancer Research Program at the Boston University Chobanian & Avedisian School of Medicine, the Karin Grunebaum Cancer Research Foundation, and the American Cancer Society (RSG-24-1321373-01-ESED). Dr. Holder received support from the Susan G. Komen Foundation [ASPIRE grant number ASP231042218]. Dr. Jones received support from the National Institutes of Health [grant number R01CA284133]. Dr. Palmer received support from the Breast Cancer Research Foundation and the Karin Grunebaum Cancer Research Foundation. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute, the National Institutes of Health, or the state cancer registries. Data availability The data needed to reproduce our findings may be shared upon approval of a data request to the Black Women’s Health Study Data Access Committee, upon approval of all relevant institutional review boards, and upon establishment of a data transfer agreement. For more information contact the corresponding author. Declarations Ethics approval and consent to participate This study was conducted in accordance with the Declaration of Helsinki. The study protocol was approved by the Boston University Medical Campus Institutional Review Board (IRB protocol number H-31535). Return of the baseline questionnaire implied informed consent. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1. Data Availability Statement The data needed to reproduce our findings may be shared upon approval of a data request to the Black Women’s Health Study Data Access Committee, upon approval of all relevant institutional review boards, and upon establishment of a data transfer agreement. For more information contact the corresponding author.